Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
REHOVOT, Israel and NEW YORK, July 27, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and six-months ended June 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, August 11.
| Conference Call & Webcast | |
| Friday, August 11th @ 10:30am Eastern Time | |
| Domestic: | 877-874-1588 |
| International: | 719-325-2499 |
| Passcode: | 9831107 |
| Webcast: | http://public.viavid.com/index.php?id=125702 |
| Replays available through August 25th: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 9831107 |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications. The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT Steven Lisi Chief Executive Officer AIT Therapeutics, Inc. [email protected] Bob Yedid LifeSci Advisors, LLC [email protected] (646) 597 6989
